Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTO: Ocrelizumab in Multiple Sclerosis Extension Study
NCT03599245Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2018
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Started Jul 2018; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03599245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599245.